Through our relentless dedication, we have emerged as frontrunners in the fields of oncology, hematology, transplant cases, and rare diseases. Since 2004, we have proudly partnered with over 15 international companies and extended our reach to several other Latin American nations.
Our primary focus is on developing and manufacturing high-quality pharmaceuticals, driven by an unwavering commitment to optimizing patient care. Our distinguished reputation stems from long-standing collaborations with the medical and scientific communities, where we prioritize innovation and continuous improvement in line with rigorous international quality standards.
registered
products worldwide
products in
Latin America
We remain committed to advancing our mission of offering broader and more effective therapeutic options for patients with Pulmonary Hypertension.
Contributing to scientific dialogue and advancing clinical practice in infectiology.
Research, debate, and collaboration: our commitment to oncology in Uruguay.
Innovation and knowledge at the European Hematology Congress in Milan, one of the most significant global events.
Participated once again in Chicago, May 30–June 3, connecting with the global oncology community.
Participated in Buenos Aires from May 7 to 10, connecting with the medical community and focusing on the benefits of Bocipal (Relugolix 40 mg).
A premier global event on April 25 and 26 at the Punta del Este Convention & Exhibition Center, focusing on the latest updates in hematology.
Participated in one of the world's most significant urology congresses from April 26 to 29 in Las Vegas, Nevada.
Varifarma Symposium: "Clinical Experience with GORAX (Relugolix 120 mg) in Advanced Prostate Cancer" at SAU Conference from April 10 to 11.
Introduced Anfonax® and Posaconazole® Varifarma at Argentina’s leading infectology congress.
Highlighting clinical experience and therapeutic benefits of Relugolix.
